Candidate Influenza Vaccines Based on Recombinant Modified Vaccinia Virus Ankara

Overview

Journal Expert Rev Vaccines

Date 2009 Apr 8

PMID 19348560

Citations 28

Authors

Guus F Rimmelzwaan

Gerd Sutter

Affiliations

Soon will be listed here.

Abstract

Recombinant modified vaccinia virus Ankara (MVA) is attractive and promising as a novel viral vector for the expression of foreign genes of interest because it possesses unique properties. In particular, its excellent safety profile and the availability of versatile vector technologies have frequently made MVA the vaccinia virus of choice for preclinical and clinical studies. Owing to its avirulence and deficiency to productively replicate after in vivo inoculation, MVA can be used under biosafety level 1 conditions. In addition to a better safety profile than replication competent vaccinia viruses, the use of MVA leads to similar levels of gene expression and has better immunostimulatory properties and improved efficacy as a recombinant vaccine. In animal models, recombinant MVA vaccines were immunogenic and induced protective immunity against various infectious agents, including viruses, bacteria and parasites. Here we review the progress that has been made in the development of recombinant MVA as a viral vector and candidate pandemic influenza H5N1 vaccine. Specifically, we will focus on the preclinical evaluation of recombinant MVA vector as pandemic influenza A/H5N1 vaccine candidates and discuss the possible future approaches for the use of these novel MVA-based vaccines.

Citing Articles

Short- and Long-Interval Prime-Boost Vaccination with the Candidate Vaccines MVA-SARS-2-ST and MVA-SARS-2-S Induces Comparable Humoral and Cell-Mediated Immunity in Mice.

Kalodimou G, Jany S, Freudenstein A, Schwarz J, Limpinsel L, Rohde C Viruses. 2023; 15(5).

PMID: 37243266 PMC: 10222707. DOI: 10.3390/v15051180.

Intranasal Delivery of MVA Vector Vaccine Induces Effective Pulmonary Immunity Against SARS-CoV-2 in Rodents.

Bosnjak B, Odak I, Barros-Martins J, Sandrock I, Hammerschmidt S, Permanyer M Front Immunol. 2021; 12:772240.

PMID: 34858430 PMC: 8632543. DOI: 10.3389/fimmu.2021.772240.

Characterisation of factors contributing to the performance of nonwoven fibrous matrices as substrates for adenovirus vectored vaccine stabilisation.

Dulal P, Gharaei R, Berg A, Walters A, Hawkins N, Claridge T Sci Rep. 2021; 11(1):20877.

PMID: 34686689 PMC: 8536692. DOI: 10.1038/s41598-021-00065-4.

Influenza A Virus Vaccination: Immunity, Protection, and Recent Advances Toward A Universal Vaccine.

Lopez C, Legge K Vaccines (Basel). 2020; 8(3).

PMID: 32756443 PMC: 7565301. DOI: 10.3390/vaccines8030434.

Next-generation influenza vaccines: opportunities and challenges.

Wei C, Crank M, Shiver J, Graham B, Mascola J, Nabel G Nat Rev Drug Discov. 2020; 19(4):239-252.

PMID: 32060419 PMC: 7223957. DOI: 10.1038/s41573-019-0056-x.

References

Drexler I, Staib C, Sutter G . Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?. Curr Opin Biotechnol. 2004; 15(6):506-12. PMC: 7127071. DOI: 10.1016/j.copbio.2004.09.001. View

Paran N, Suezer Y, Lustig S, Israely T, Schwantes A, Melamed S . Postexposure immunization with modified vaccinia virus Ankara or conventional Lister vaccine provides solid protection in a murine model of human smallpox. J Infect Dis. 2008; 199(1):39-48. DOI: 10.1086/595565. View

Kuiken T, Holmes E, McCauley J, Rimmelzwaan G, Williams C, Grenfell B . Host species barriers to influenza virus infections. Science. 2006; 312(5772):394-7. DOI: 10.1126/science.1122818. View

STICKL H, Hochstein-Mintzel V . [Intracutaneous smallpox vaccination with a weak pathogenic vaccinia virus ("MVA virus")]. Munch Med Wochenschr. 1971; 113(35):1149-53. View

Mayr A, STICKL H, Muller H, Danner K, Singer H . [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)]. Zentralbl Bakteriol B. 1978; 167(5-6):375-90. View

Hirsch V, Fuerst T, Sutter G, Carroll M, Yang L, Goldstein S . Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J Virol. 1996; 70(6):3741-52. PMC: 190250. DOI: 10.1128/JVI.70.6.3741-3752.1996. View

Ferrier-Rembert A, Drillien R, Tournier J, Garin D, Crance J . Short- and long-term immunogenicity and protection induced by non-replicating smallpox vaccine candidates in mice and comparison with the traditional 1st generation vaccine. Vaccine. 2008; 26(14):1794-804. DOI: 10.1016/j.vaccine.2007.12.059. View

Carroll M, Moss B . Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology. 1997; 238(2):198-211. DOI: 10.1006/viro.1997.8845. View

Stittelaar K, Kuiken T, de Swart R, van Amerongen G, Vos H, Niesters H . Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. Vaccine. 2001; 19(27):3700-9. DOI: 10.1016/s0264-410x(01)00075-5. View

10.

Mooij P, Balla-Jhagjhoorsingh S, Koopman G, Beenhakker N, van Haaften P, Baak I . Differential CD4+ versus CD8+ T-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates. J Virol. 2008; 82(6):2975-88. PMC: 2258966. DOI: 10.1128/JVI.02216-07. View

11.

Earl P, Americo J, Wyatt L, Espenshade O, Bassler J, Gong K . Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus. Proc Natl Acad Sci U S A. 2008; 105(31):10889-94. PMC: 2495015. DOI: 10.1073/pnas.0804985105. View

12.

Samuelsson C, Hausmann J, Lauterbach H, Schmidt M, Akira S, Wagner H . Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection. J Clin Invest. 2008; 118(5):1776-84. PMC: 2289795. DOI: 10.1172/JCI33940. View

13.

Claas E, Osterhaus A, Van Beek R, de Jong J, Rimmelzwaan G, Senne D . Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet. 1998; 351(9101):472-7. DOI: 10.1016/S0140-6736(97)11212-0. View

14.

Kreijtz J, Suezer Y, de Mutsert G, van den Brand J, van Amerongen G, Schnierle B . Recombinant modified vaccinia virus Ankara expressing the hemagglutinin gene confers protection against homologous and heterologous H5N1 influenza virus infections in macaques. J Infect Dis. 2008; 199(3):405-13. DOI: 10.1086/595984. View

15.

Parrino J, McCurdy L, Larkin B, Gordon I, Rucker S, Enama M . Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals. Vaccine. 2006; 25(8):1513-25. PMC: 1892755. DOI: 10.1016/j.vaccine.2006.10.047. View

16.

Hawkridge T, Scriba T, Gelderbloem S, Smit E, Tameris M, Moyo S . Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J Infect Dis. 2008; 198(4):544-52. PMC: 2822902. DOI: 10.1086/590185. View

17.

Drexler I, Heller K, Wahren B, Erfle V, Sutter G . Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol. 1998; 79 ( Pt 2):347-52. DOI: 10.1099/0022-1317-79-2-347. View

18.

Bender B, Rowe C, Taylor S, Wyatt L, Moss B, Small Jr P . Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza. J Virol. 1996; 70(9):6418-24. PMC: 190672. DOI: 10.1128/JVI.70.9.6418-6424.1996. View

19.

Guerra S, Najera J, Gonzalez J, Lopez-Fernandez L, Climent N, Gatell J . Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC. J Virol. 2007; 81(16):8707-21. PMC: 1951336. DOI: 10.1128/JVI.00444-07. View

20.

Staib C, Lowel M, Erfle V, Sutter G . Improved host range selection for recombinant modified vaccinia virus Ankara. Biotechniques. 2003; 34(4):694-6, 698, 700. DOI: 10.2144/03344bm02. View